OBJECTIVE: To examine the relation of cerebral amyloid angiopathy (CAA) to cognitive domains in older community-dwelling persons with and without dementia. METHODS: Subjects were 404 persons in the Religious Orders Study, a cohort study of aging, who underwent annual clinical evaluations, including 19 neuropsychological tests from which 5 cognitive domain and global summary scores were derived, and brain autopsy at time-of-death (mean age-at-death 86). Using amyloid-β immunostaining, CAA severity was graded in 5 regions (midfrontal, inferior temporal, angular, calcarine, and hippocampal cortices), as 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe. Because severity was related across regions (all r(s) > 0.63), and almost all persons had some CAA, we averaged regional CAA scores and created class variable predictors for no-to-minimal (<0.5), mild-to-moderate (0.5-2.5) and moderate-to-very severe CAA (>2.5). RESULTS: CAA was very common (84.9%; 94 had no-to-minimal, 233 mild-to-moderate, and 76 moderate-to-very severe disease) and was related to AD pathology (r(s) = 0.68). In linear regression analyses controlling for age, sex, education, AD pathology, infarcts, and Lewy bodies, moderate-to-very severe CAA was associated with lower perceptual speed (p = 0.012) and episodic memory (p = 0.047), but not semantic memory, working memory, visuospatial skills, or a composite of all cognitive measures. No associations of mild-to-moderate CAA with cognition were found. Dementia did not modify these findings. INTERPRETATION: CAA pathology is very common in older community-dwelling persons and is associated with AD pathology. Moderate-to-very severe CAA, but not mild-to-moderate CAA, is associated with lower performance in specific cognitive domains, most notably perceptual speed, separately from the effect of AD pathology.
OBJECTIVE: To examine the relation of cerebral amyloid angiopathy (CAA) to cognitive domains in older community-dwelling persons with and without dementia. METHODS: Subjects were 404 persons in the Religious Orders Study, a cohort study of aging, who underwent annual clinical evaluations, including 19 neuropsychological tests from which 5 cognitive domain and global summary scores were derived, and brain autopsy at time-of-death (mean age-at-death 86). Using amyloid-β immunostaining, CAA severity was graded in 5 regions (midfrontal, inferior temporal, angular, calcarine, and hippocampal cortices), as 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe. Because severity was related across regions (all r(s) > 0.63), and almost all persons had some CAA, we averaged regional CAA scores and created class variable predictors for no-to-minimal (<0.5), mild-to-moderate (0.5-2.5) and moderate-to-very severe CAA (>2.5). RESULTS: CAA was very common (84.9%; 94 had no-to-minimal, 233 mild-to-moderate, and 76 moderate-to-very severe disease) and was related to AD pathology (r(s) = 0.68). In linear regression analyses controlling for age, sex, education, AD pathology, infarcts, and Lewy bodies, moderate-to-very severe CAA was associated with lower perceptual speed (p = 0.012) and episodic memory (p = 0.047), but not semantic memory, working memory, visuospatial skills, or a composite of all cognitive measures. No associations of mild-to-moderate CAA with cognition were found. Dementia did not modify these findings. INTERPRETATION: CAA pathology is very common in older community-dwelling persons and is associated with AD pathology. Moderate-to-very severe CAA, but not mild-to-moderate CAA, is associated with lower performance in specific cognitive domains, most notably perceptual speed, separately from the effect of AD pathology.
Authors: Tom Jeerakathil; Philip A Wolf; Alexa Beiser; John K Hald; Rhoda Au; Carlos S Kase; Joseph M Massaro; Charles DeCarli Journal: Stroke Date: 2004-05-20 Impact factor: 7.914
Authors: Robert S Wilson; Carlos F Mendes De Leon; Lisa L Barnes; Julie A Schneider; Julia L Bienias; Denis A Evans; David A Bennett Journal: JAMA Date: 2002-02-13 Impact factor: 56.272
Authors: D A Bennett; R S Wilson; J A Schneider; D A Evans; L A Beckett; N T Aggarwal; L L Barnes; J H Fox; J Bach Journal: Neurology Date: 2002-07-23 Impact factor: 9.910
Authors: D A Bennett; R S Wilson; J A Schneider; D A Evans; N T Aggarwal; S E Arnold; E J Cochran; E Berry-Kravis; J L Bienias Journal: Neurology Date: 2003-01-28 Impact factor: 9.910
Authors: Robert S Wilson; Laurel A Beckett; Lisa L Barnes; Julie A Schneider; Julie Bach; Denis A Evans; David A Bennett Journal: Psychol Aging Date: 2002-06
Authors: Eric D Vidoni; Hung-Wen Yeh; Jill K Morris; Kathy L Newell; Abdulfattah Alqahtani; Nicole C Burns; Jeffrey M Burns; Sandra A Billinger Journal: Neurodegener Dis Date: 2016-01-13 Impact factor: 2.977
Authors: Valerie Valant; Brendan T Keenan; Christopher D Anderson; Joshua M Shulman; William J Devan; Alison M Ayres; Kristin Schwab; Joshua N Goldstein; Anand Viswanathan; Steven M Greenberg; David A Bennett; Philip L De Jager; Jonathan Rosand; Alessandro Biffi Journal: Transl Stroke Res Date: 2012-04-12 Impact factor: 6.829
Authors: Robert J Dawe; David A Bennett; Julie A Schneider; Sue E Leurgans; Aikaterini Kotrotsou; Patricia A Boyle; Konstantinos Arfanakis Journal: Neurobiol Aging Date: 2014-02-06 Impact factor: 4.673
Authors: Robert J Dawe; Lei Yu; Julie A Schneider; Konstantinos Arfanakis; David A Bennett; Patricia A Boyle Journal: Neurobiol Aging Date: 2018-05-23 Impact factor: 4.673
Authors: Veronika Hanko; Alexandra C Apple; Kathryn I Alpert; Kristen N Warren; Julie A Schneider; Konstantinos Arfanakis; David A Bennett; Lei Wang Journal: Neurobiol Aging Date: 2018-10-25 Impact factor: 4.673